Orthocell Ltd (AU:OCC) has released an update.
Orthocell Ltd has announced the TGA application for its third revenue-generating product, SmrtGraft™, aimed at tendon repair and regeneration in the Australian market. SmrtGraft™ has shown to reduce revision surgery rates in tendon repairs, indicating its effectiveness and potential in a market worth over US$1.2 billion annually. With a strategy to expand into other key markets following Australia, Orthocell is poised to make significant strides in the regenerative medicine field with its innovative product lineup.
For further insights into AU:OCC stock, check out TipRanks’ Stock Analysis page.
